In Vitro Activities of Tigecycline against the Bacteroides fragilis Group
Open Access
- 1 March 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (3), 1034-1036
- https://doi.org/10.1128/aac.48.3.1034-1036.2004
Abstract
The in vitro activities of tigecycline were tested against 831 isolates of the Bacteroides fragilis group representing all of the species within the group. On a weight-to-weight basis (8 μg/ml), tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Tigecycline geometric mean MICs were statistically higher against B. distasonis than other Bacteroides species ( P value of 0.0001).Keywords
This publication has 10 references indexed in Scilit:
- In Vitro Activities of Newer Quinolones against Bacteroides Group OrganismsAntimicrobial Agents and Chemotherapy, 2002
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in SpainAntimicrobial Agents and Chemotherapy, 2002
- Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas , and Peptostreptococcus SpeciesAntimicrobial Agents and Chemotherapy, 2001
- Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilis Group: Effect of the Medium on Test ResultsAntimicrobial Agents and Chemotherapy, 2000
- In-vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcyclineClinical Microbiology & Infection, 2000
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000
- In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)Antimicrobial Agents and Chemotherapy, 1999
- Analysis of Trends in Antimicrobial Resistance Patterns Among Clinical Isolates of Bacteroides fragilis Group Species from 1990 to 1994Clinical Infectious Diseases, 1996
- In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclinesAntimicrobial Agents and Chemotherapy, 1993